Drug Trial Radar · NCT07439510
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Feb 1, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- SpinogenixIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Study to Investigate the Effects and Safety of Codabakalner for the Treatment of Fragile X Syndrome in Male Participants and Adult Participants with Autism Spectrum Disorders
Conditions
- Fragile X Syndrome (FXS)
- Autism Spectrum Disorder (ASD)
Interventions
CodabakalnerDrug
synthetic small molecule
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCBTime frame: 28 days
- Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite ScoreTime frame: 28 days
- Phase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCBTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.